Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells

Bender, 1991, Use of a screen for synthetic lethal and multicopy suppressee mutants to identify two new genes involved in morphogenesis in Saccharomyces cerevisiae, Mol. Cell. Biol., 11, 1295 Bernards, 2006, shRNA libraries and their use in cancer genetics, Nat. Methods, 3, 701, 10.1038/nmeth921 Bild, 2006, Oncogenic pathway signatures in human cancers as a guide to targeted therapies, Nature, 439, 353, 10.1038/nature04296 Boehm, 2007, Integrative genomic approaches identify IKBKE as a breast cancer oncogene, Cell, 129, 1065, 10.1016/j.cell.2007.03.052 Bowen, 2005, RAS mutation in acute myeloid leukemia is associated with distinct cytogenetic subgroups but does not influence outcome in patients younger than 60 years, Blood, 106, 2113, 10.1182/blood-2005-03-0867 Chen, 1995, DLD-1 and HCT-15 cell lines derived separately from colorectal carcinomas have totally different chromosome changes but the same genetic origin, Cancer Genet. Cytogenet., 81, 103, 10.1016/0165-4608(94)00225-Z Cragg, 2008, Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic, J. Clin. Invest., 118, 3651, 10.1172/JCI35437 Crowder, 2003, An unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth, Oncogene, 22, 649, 10.1038/sj.onc.1206180 DeBerardinis, 2008, The biology of cancer: metabolic reprogramming fuels cell growth and proliferation, Cell Metab., 7, 11, 10.1016/j.cmet.2007.10.002 Demunter, 2001, A novel N-ras mutation in malignant melanoma is associated with excellent prognosis, Cancer Res., 61, 4916 Demunter, 2001, Analysis of N- and K-ras mutations in the distinctive tumor progression phases of melanoma, J. Invest. Dermatol., 117, 1483, 10.1046/j.0022-202x.2001.01601.x Djouder, 2007, S6K1-mediated disassembly of mitochondrial URI/PP1gamma complexes activates a negative feedback program that counters S6K1 survival signaling, Mol. Cell, 28, 28, 10.1016/j.molcel.2007.08.010 Downward, 2004, Use of RNA interference libraries to investigate oncogenic signalling in mammalian cells, Oncogene, 23, 8376, 10.1038/sj.onc.1208073 Faivre, 2006, Current development of mTOR inhibitors as anticancer agents, Nat. Rev. Drug Discov., 5, 671, 10.1038/nrd2062 Firestein, 2008, CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity, Nature, 455, 547, 10.1038/nature07179 Greenman, 2007, Patterns of somatic mutation in human cancer genomes, Nature, 446, 153, 10.1038/nature05610 Guertin, 2007, Defining the role of mTOR in cancer, Cancer Cell, 12, 9, 10.1016/j.ccr.2007.05.008 Harada, 2001, p70S6 kinase signals cell survival as well as growth, inactivating the pro-apoptotic molecule BAD, Proc. Natl. Acad. Sci. USA, 98, 9666, 10.1073/pnas.171301998 Hartwell, 1997, Integrating genetic approaches into the discovery of anticancer drugs, Science, 278, 1064, 10.1126/science.278.5340.1064 Jimeno, 2008, Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer, Cancer Res., 68, 2841, 10.1158/0008-5472.CAN-07-5200 Jones, 2008, Core signaling pathways in human pancreatic cancers revealed by global genomic analyses, Science, 321, 1801, 10.1126/science.1164368 Kaelin, 2005, The concept of synthetic lethality in the context of anticancer therapy, Nat. Rev. Cancer, 5, 689, 10.1038/nrc1691 Karnoub, 2008, Ras oncogenes: split personalities, Nat. Rev. Mol. Cell Biol., 9, 517, 10.1038/nrm2438 Kim, 2002, mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery, Cell, 110, 163, 10.1016/S0092-8674(02)00808-5 Koinuma, 2006, Epigenetic silencing of AXIN2 in colorectal carcinoma with microsatellite instability, Oncogene, 25, 139, 10.1038/sj.onc.1209009 Ley, 2005, Regulatory phosphorylation of Bim: sorting out the ERK from the JNK, Cell Death Differ., 12, 1008, 10.1038/sj.cdd.4401688 Lin, 1998, Mutations of K-ras oncogene in human adrenal tumours in Taiwan, Br. J. Cancer, 77, 1060, 10.1038/bjc.1998.177 Lin, 2000, Decreased GTPase activity of K-ras mutants deriving from human functional adrenocortical tumours, Br. J. Cancer, 82, 1035, 10.1054/bjoc.1999.1039 Lucchesi, 1968, Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanogaster, Genetics, 59, 37, 10.1093/genetics/59.1.37 Moffat, 2006, A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen, Cell, 124, 1283, 10.1016/j.cell.2006.01.040 Mujica, 2001, A novel serine/threonine kinase gene, STK33, on human chromosome 11p15.3, Gene, 280, 175, 10.1016/S0378-1119(01)00780-6 Ngo, 2006, A loss-of-function RNA interference screen for molecular targets in cancer, Nature, 441, 106, 10.1038/nature04687 Parsons, 2008, An integrated genomic analysis of human glioblastoma multiforme, Science, 321, 1807, 10.1126/science.1164382 Pei, 1994, H-ras mutations in human pituitary carcinoma metastases, J. Clin. Endocrinol. Metab., 78, 842 Roberts, 2007, Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer, Oncogene, 26, 3291, 10.1038/sj.onc.1210422 Rocnik, 2006, Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD, Blood, 108, 1339, 10.1182/blood-2005-11-011429 Root, 2006, Genome-scale loss-of-function screening with a lentiviral RNAi library, Nat. Methods, 3, 715 Rottmann, 2005, A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function, Proc. Natl. Acad. Sci. USA, 102, 15195, 10.1073/pnas.0505114102 Ruvinsky, 2006, Ribosomal protein S6 phosphorylation: from protein synthesis to cell size, Trends Biochem. Sci., 31, 342, 10.1016/j.tibs.2006.04.003 Sarthy, 2007, Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells, Mol. Cancer Ther., 6, 269, 10.1158/1535-7163.MCT-06-0560 Sawyers, 2004, Targeted cancer therapy, Nature, 432, 294, 10.1038/nature03095 Schalm, 2005, Characterization of a conserved C-terminal motif (RSPRR) in ribosomal protein S6 kinase 1 required for its mammalian target of rapamycin-dependent regulation, J. Biol. Chem., 280, 11101, 10.1074/jbc.M413995200 Schlabach, 2008, Cancer proliferation gene discovery through functional genomics, Science, 319, 620, 10.1126/science.1149200 Schubbert, 2007, Hyperactive Ras in developmental disorders and cancer, Nat. Rev. Cancer, 7, 295, 10.1038/nrc2109 Shaffer, 2008, IRF4 addiction in multiple myeloma, Nature, 454, 226, 10.1038/nature07064 Shaw, 2006, Ras, PI(3)K and mTOR signalling controls tumour cell growth, Nature, 441, 424, 10.1038/nature04869 Shirasawa, 1993, Altered growth of human colon cancer cell lines disrupted at activated Ki-ras, Science, 260, 85, 10.1126/science.8465203 Silva, 2008, Profiling essential genes in human mammary cells by multiplex RNAi screening, Science, 319, 617, 10.1126/science.1149185 Simons, 2001, Establishment of a chemical synthetic lethality screen in cultured human cells, Genome Res., 11, 266, 10.1101/gr.154201 Smakman, 2006, KRAS(D13) Promotes apoptosis of human colorectal tumor cells by ReovirusT3D and oxaliplatin but not by tumor necrosis factor-related apoptosis-inducing ligand, Cancer Res., 66, 5403, 10.1158/0008-5472.CAN-05-4108 Solimini, 2007, Non-oncogene addiction and the stress phenotype of cancer cells, Cell, 130, 986, 10.1016/j.cell.2007.09.007 Solit, 2006, BRAF mutation predicts sensitivity to MEK inhibition, Nature, 439, 358, 10.1038/nature04304 Stockwell, 1999, High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications, Chem. Biol., 6, 71, 10.1016/S1074-5521(99)80004-0 Suzuki, 1990, Detection of ras gene mutations in human lung cancers by single-strand conformation polymorphism analysis of polymerase chain reaction products, Oncogene, 5, 1037 Torrance, 2001, Use of isogenic human cancer cells for high-throughput screening and drug discovery, Nat. Biotechnol., 19, 940, 10.1038/nbt1001-940 Turner, 2008, A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor, EMBO J., 27, 1368, 10.1038/emboj.2008.61 Varjosalo, 2008, Application of active and kinase-deficient kinome collection for identification of kinases regulating hedgehog signaling, Cell, 133, 537, 10.1016/j.cell.2008.02.047 Wang, 2006, Molecular mechanisms underlying the tumorigenesis of colorectal adenomas: correlation to activated K-ras oncogene, Oncol. Rep., 16, 1245 Westbrook, 2005, Dissecting cancer pathways and vulnerabilities with RNAi, Cold Spring Harb. Symp. Quant. Biol., 70, 435, 10.1101/sqb.2005.70.031 Whitehurst, 2007, Synthetic lethal screen identification of chemosensitizer loci in cancer cells, Nature, 446, 815, 10.1038/nature05697 Wood, 2007, The genomic landscapes of human breast and colorectal cancers, Science, 318, 1108, 10.1126/science.1145720 Yagoda, 2007, RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels, Nature, 447, 864, 10.1038/nature05859 Zha, 1996, Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L), Cell, 87, 619, 10.1016/S0092-8674(00)81382-3